WO1999063976A3 - Liver-selective glucocorticoid antagonist for treating diabetes - Google Patents

Liver-selective glucocorticoid antagonist for treating diabetes Download PDF

Info

Publication number
WO1999063976A3
WO1999063976A3 PCT/IB1999/001175 IB9901175W WO9963976A3 WO 1999063976 A3 WO1999063976 A3 WO 1999063976A3 IB 9901175 W IB9901175 W IB 9901175W WO 9963976 A3 WO9963976 A3 WO 9963976A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver
treating diabetes
glucocorticoid antagonist
selective glucocorticoid
diabetes
Prior art date
Application number
PCT/IB1999/001175
Other languages
French (fr)
Other versions
WO1999063976A2 (en
Inventor
Theresa Apelqvist
Suad Efendic
Original Assignee
Karobio Ab
Theresa Apelqvist
Suad Efendic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812314.4A external-priority patent/GB9812314D0/en
Priority claimed from GBGB9815149.1A external-priority patent/GB9815149D0/en
Application filed by Karobio Ab, Theresa Apelqvist, Suad Efendic filed Critical Karobio Ab
Priority to IL13986599A priority Critical patent/IL139865A0/en
Priority to JP2000553045A priority patent/JP2002527355A/en
Priority to KR1020007013430A priority patent/KR20010052431A/en
Priority to CA002334116A priority patent/CA2334116A1/en
Priority to AU41606/99A priority patent/AU751569B2/en
Priority to EP99925232A priority patent/EP1143948A3/en
Publication of WO1999063976A2 publication Critical patent/WO1999063976A2/en
Publication of WO1999063976A3 publication Critical patent/WO1999063976A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Use of a liver-selective glucocorticoid antagonist, preferably the compound having formula (I) in the preparation of a pharmaceutical composition for the treatment of diabetes. A composition for the treatment of diabetes containing such a glucocorticoid antagonist, and a method of treating diabetes using the composition.
PCT/IB1999/001175 1998-06-08 1999-06-07 Liver-selective glucocorticoid antagonist for treating diabetes WO1999063976A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL13986599A IL139865A0 (en) 1998-06-08 1999-06-07 A liver selective glucocorticoid antagonist and pharmaceutical compositions containing the same
JP2000553045A JP2002527355A (en) 1998-06-08 1999-06-07 Diabetes treatment
KR1020007013430A KR20010052431A (en) 1998-06-08 1999-06-07 Treatment of diabetes
CA002334116A CA2334116A1 (en) 1998-06-08 1999-06-07 Treatment of diabetes
AU41606/99A AU751569B2 (en) 1998-06-08 1999-06-07 Treatment of diabetes
EP99925232A EP1143948A3 (en) 1998-06-08 1999-06-07 Liver-selective glucocorticoid antagonist for treating diabetes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9812314.4 1998-06-08
GBGB9812314.4A GB9812314D0 (en) 1998-06-08 1998-06-08 Treatment of diabetes
GB9815149.1 1998-07-13
GBGB9815149.1A GB9815149D0 (en) 1998-07-13 1998-07-13 Treatment of diabetes

Publications (2)

Publication Number Publication Date
WO1999063976A2 WO1999063976A2 (en) 1999-12-16
WO1999063976A3 true WO1999063976A3 (en) 2001-12-20

Family

ID=26313822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001175 WO1999063976A2 (en) 1998-06-08 1999-06-07 Liver-selective glucocorticoid antagonist for treating diabetes

Country Status (7)

Country Link
EP (1) EP1143948A3 (en)
JP (1) JP2002527355A (en)
KR (1) KR20010052431A (en)
AU (1) AU751569B2 (en)
CA (1) CA2334116A1 (en)
IL (1) IL139865A0 (en)
WO (1) WO1999063976A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9907048D0 (en) 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
ATE303369T1 (en) 2000-10-30 2005-09-15 Pfizer Prod Inc GLUCOCORTICOID RECEPTOR MODULATORS
GB0029100D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029102D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
AU2002219192A1 (en) * 2000-12-20 2002-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
WO2002064550A1 (en) * 2001-02-14 2002-08-22 Abbott Laboratories Glucocorticoid receptor modulators
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
EP1285927A3 (en) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Use of glucocorticoid antagonists for the prevention and treatment of diseases of the male reproductive system
JP2005539208A (en) * 2001-12-21 2005-12-22 スミスクライン ビーチャム コーポレーション Compositions and methods for altering glucose production
EA008830B1 (en) 2002-03-26 2007-08-31 Бёрингер Ингельхайм Фармасьютиклз, Инк. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1653256B1 (en) 2003-07-31 2012-02-15 Soken Chemical & Engineering Co. Ltd., Fluid colloid crystal and process for producing three-dimensional aligned particle mass therefrom
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
DE602005015027D1 (en) 2004-12-27 2009-07-30 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
MX2009005264A (en) 2006-12-06 2009-05-28 Boehringer Ingelheim Int Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof.
US8268859B2 (en) 2008-06-06 2012-09-18 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US8138189B2 (en) * 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
CA2769563A1 (en) 2009-07-31 2011-02-10 Cadila Healthcare Limited Novel compounds as modulators of glucocorticoid receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374148A (en) * 1980-10-21 1983-02-15 Pfizer Inc. Carboxylic acid therapeutic agents
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374148A (en) * 1980-10-21 1983-02-15 Pfizer Inc. Carboxylic acid therapeutic agents
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHASSEROT-GOLAZ S ET AL: "Metabolism and antiproliferative effect of the glucocorticoid antagonist RU38486 in cultured liver and hepatoma cells.", JOURNAL OF STEROID BIOCHEMISTRY, (1986 JAN) 24 (1) 423-6., XP002117767 *
GETTYS ET AL.: "Ru-486 (mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signalling in adipocytes from mature C57Bl/6J-ob/ob mice", INT. J. OBESITY, vol. 21, no. 10, 1997, pages 865 - 873, XP002117766 *

Also Published As

Publication number Publication date
AU4160699A (en) 1999-12-30
WO1999063976A2 (en) 1999-12-16
IL139865A0 (en) 2002-02-10
JP2002527355A (en) 2002-08-27
EP1143948A2 (en) 2001-10-17
CA2334116A1 (en) 1999-12-16
AU751569B2 (en) 2002-08-22
KR20010052431A (en) 2001-06-25
EP1143948A3 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
DE69726577D1 (en) Kristallin form i von clarithromycin
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
HUP0203122A3 (en) Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
AU3945197A (en) Novel stable liquid paracetamol compositions, and method for preparing same
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
AU8693098A (en) Compositions and methods for treating diabetes
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
AU1890295A (en) Piperidines and pyrrolidines
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
AU9624198A (en) Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
AU3892593A (en) Composition for therapeutic or diagnostic use, process for its preparation and its use
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU7423194A (en) Novel estradiol derivative-alkylating agent conjugate with reduced hormonal activity, process for preparing the same, compounds useful for the preparation thereof, and growth inhibiting composition containing the conjugate or estradiol derivative
HUP0101098A3 (en) Streptogramin derivatives, process for preparation thereof and compositions containing same
AU5116590A (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
AU5218398A (en) Compositions for treating soils, method of preparation and use thereof
AU2620995A (en) Oxathiolanes, method for their preparation and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999925232

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 41606/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020007013430

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2334116

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09700783

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007013430

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999925232

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 41606/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999925232

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007013430

Country of ref document: KR